Melvin Hayes - 26 Apr 2023 Form 4 Insider Report for Fulcrum Therapeutics, Inc. (FULC)

Role: Chief Operating Officer
Signature: /s/ Gregory Tourangeau, as attorney-in-fact for Melvin Hayes
Issuer symbol: FULC
Transactions as of: 26 Apr 2023
Net transactions value: $0
Form type: 4
Filing time: 28 Apr 2023, 16:17:16 UTC
Previous filing: 13 Feb 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FULC	Stock Option (right to buy)	Award	$0	+115,000		$0.000000	115,000	26 Apr 2023	Common Stock	115,000	$2.58	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These stock options were granted to the reporting person under the Fulcrum 2019 Stock Incentive Plan (the "Plan") as part of an executive retention program and will vest 25% on the first anniversary of the grant date. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years, such that the options will be vested in full on the four-year anniversary of the grant date, and subject to the reporting person's continuing to be an "Eligible Participant" (as defined in the Plan) on each such vesting date.

Content

These stock options were granted to the reporting person under the Fulcrum 2019 Stock Incentive Plan (the "Plan") as part of an executive retention program and will vest 25% on the first anniversary of the grant date. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years, such that the options will be vested in full on the four-year anniversary of the grant date, and subject to the reporting person's continuing to be an "Eligible Participant" (as defined in the Plan) on each such vesting date.